LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

B.C. Cho; M-J. Ahn; J.H. Kang; R. Soo; T. Baisamut (Reungwetwattana); J.C-H. Yang; I. Cicin; D-W. Kim; Y-L. Wu; S. Lu; K. Lee; Y-K. Pang; A. Zimina; C.H. Fong; E. Poddubskaya; Y. Kim; T. An; H. Lee; H. Byun; B. Zaric

doi:10.1016/j.annonc.2022.10.349

YUHSpace

BROWSE

0 204

Cited 0 times in

LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

Authors: B.C. Cho ; M-J. Ahn ; J.H. Kang ; R. Soo ; T. Baisamut (Reungwetwattana) ; J.C-H. Yang ; I. Cicin ; D-W. Kim ; Y-L. Wu ; S. Lu ; K. Lee ; Y-K. Pang ; A. Zimina ; C.H. Fong ; E. Poddubskaya ; Y. Kim ; T. An ; H. Lee ; H. Byun ; B. Zaric